CRM — long thesis
Thesis
Salesforce is down ~30% YTD but near cost basis for this position. The value thesis rests on: (1) a $25B share buyback program providing downside support, (2) Agentforce AI platform as a potential re-rating catalyst with earnings due May 27, (3) analyst consensus Buy with avg PT of ~$279 implying ~50% upside from current levels, and (4) enterprise software broadly recovering with Atlassian's 28% earnings beat demonstrating enterprise AI spend is real. Key risks include decelerating organic growth (CRM market share fell from 21.7% to 20.7%), activist pressure (Starboard Value proxy fight at May 28 annual meeting), and high-single-digit organic growth being priced as a premium software name. The May 27 earnings report is the key catalyst.
Triggers
Entry: Already held — adopted into thesis management
Exit: Exit partially if CRM reaches $220-240 (halfway to consensus PT). Exit fully if May 27 earnings show Agentforce traction is failing to convert to revenue or if organic growth falls below 7%. Hold through earnings if pre-earnings sentiment is constructive.
Invalidation: Q1 FY27 (May 27) earnings showing organic revenue growth below 8%; Agentforce deal pipeline failing to convert; market share losses accelerating; stock breaking below $165 support level.